The CIBMTR Audit Program



Similar documents
Preparing for the CIBMTR Data Audit

Karnofsky/Lansky Performance Status

Bone Marrow/Stem Cell Transplant

11/10/2011. History of CBUs. 10-CBA providing access to unlicensed cord blood units. The FDA s involvement. The FDA s involvement, cont.

Kathie Viers-City of Hope Eric Presson- Baylor Health Care Systems Jennifer Christian-Markay Cancer Center

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Corporate Medical Policy Cord Blood as a Source of Stem Cells

EUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases

Background: 1) Does your center have effective ways of collecting data from multiple sources to submit to multiple organizations?

Instructions for Pre-Transplant Essential Data (Pre-TED) Form (Revision 4) TABLE OF CONTENTS

Hematologic Malignancies/Stem Cell Transplantation Program Clinical Section UCLA Health System Los Angeles, CA 90095

Corporate Medical Policy

Corporate Medical Policy

Department of Veterans Affairs VHA DIRECTIVE Veterans Health Administration Washington, DC July 9, 2012

STEM CELL THERAPEUTIC OUTCOMES DATABASE

CORD BLOOD TRANSPLANTATION STUDY EXPANDED ACCESS PROTOCOL APPENDIX A SAMPLE CONSENT FORM

Integrating Quality Reporting into the Electronic Medical Record

Data Reporting Problems

storage and handling of unused stem cell products Swiss consensus?

Anthem Centers of Medical Excellence (CME) Transplant Network. CONTRACT OPERATIONS MANUAL for Transplant Program

Beyond Electronic Data Capture (EDC) to Data Sharing: Update of Selected ASBMT/CIBMTR/NMDP IT Programs. Roy B. Jones, PhD MD

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between

OUR JOURNEY THROUGH THE YEARS

A Cure for Sickle Cell Anemia and Thalassemia

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Corporate Medical Policy

Table of Contents. FACT Quality Handbook, Second Edition. Table of Contents

INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR

Cord blood donation is a painless and free gesture, helping others and saving lives.

Umbilical Cord Blood Stem Cells Current Status & Future Potential

Hematologic Malignancies/Stem Cell Transplantation Program Clinical Section UCLA Health System Los Angeles, CA 90095

National Patient Safety Goals Effective January 1, 2015

STEM CELL TRANSPLANTS

CIBMTR Infection Data and the New Infection Inserts.

Quality Monitoring Checklist

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma

National Patient Safety Goals Effective January 1, 2015

Disclosures. I have no disclosures.

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

Blood-Forming Stem Cell Transplants

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

Cord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program

Umbilical Cord Blood Transplantation

Infosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?

The Danish Bone Marrow Donor Registry DBMDR

How To Safely Infuse Aupbsc

Abstract. 1. Basic underlying view

Reference: NHS England B04/P/a

Cord Blood: Thawing & Infusion Practical Methods

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape

CPT Codes for Bone Marrow Transplant January 2015 James L. Gajewski, MD

5th Edition NetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration. Summary of Changes

EMS Example Example EMS Audit Procedure

IV Thiotepa/Busulfan/Fludarabine/ATG for Allograft

Outcome of Unrelated HSCT in Patients Lacking HLA Matched Related Donors: Iranian Stem Cell Donor Program (ISCDP)

How To Improve Health Care For An Hiv Patient

IBCSG Tissue Bank Policy

Cord Blood Stem Cell Transplantation

Data Management in Clinical Trials

Jennifer Collins, RN Quality Liaison Ann & Robert H. Lurie Children's Hospital of Chicago

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION

The role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations

»medical programs and services. transfusion medicine fellowship program

New Zealand Bone Marrow Donor Registry

Selection of the Optimal Umbilical Cord Blood Unit

Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012

Directed, Autologous and Therapeutic Donations

PANCREAS, PANCREAS-KIDNEY, SEGMENT OF PANCREAS AND ISLET PANCREATIC TISSUE TRANSPLANTATION SUR

STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005

Cyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft

The future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings. Prof. Tony Pagliuca

Integrated Medical Record System for Nephrology

4/25/2016. Transplant Journey. Objectives. Reason for Transplantation at Mayo Clinic. Mayo Clinic Model of Care

Appropriate Modifier Usage

How To Transplant Cord Blood

Hematopoietic stem and progenitor cell transplants: regulation and accreditation

Inspection Guide for WMDA reviewers

Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose

Collaborative Practice Agreement for Nurse Practitioner Management of Patients in the Specialty of Pediatric Critical Care

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa

Reconciling the Differences. Karen Lippett B.Sc.Phm Humber River Regional Hospital Renal Dialysis Unit

Improving Quality in Cellular Therapy with FACT Accreditation. The Foundation for the Accreditation of Cellular Therapy

Transcription:

The CIBMTR Audit Program Amy Hays and Krista Sullivan November 7, 2008

Objectives Audit rationale and goals Overview of audit program Audit process Audit follow-up

Why are audits performed?

Audit Rationale Data audits are performed at CIBMTR Transplant Centers as part of the CIBMTR s overall data quality assurance program

What are the goals of an audit?

Audit Goals Quality/accuracy of research database Identify systematic/non-systematic errors Implement systems to help prevent errors Additional training for transplant centers

Why we audit

Stem Cell Therapeutic Outcomes Database (SCTOD) CIBMTR awarded contract for SCTOD Component of C. W. Bill Young Cell Transplantation Program Outcomes data collected on all transplant recipients where either donor or recipient resides in U.S. All allogeneic transplants, both related and unrelated

CIBMTR Audit Program

Overview One comprehensive audit program Each center audited once in 4 year cycle Minimum of 20 eligible recipients; minimum of 16 audited Combination of allogeneic related, allogeneic unrelated, and autologous transplants 3-4 day audit performed by 1-2 auditors

Audit Frequency Transplant centers will be audited once in a four year cycle

Audit Eligibility Transplant Center Eligibility 20 transplants have been completed Patient Eligibility Pre & Post-TED, and/or Baseline & 100 day follow-up form in database and error-free Minimum of 16 recipient records audited at each transplant center

Audit Eligibility, cont. Recipients only audited once Only recipients transplanted since last audit date are eligible For new centers all recipients will be For new centers, all recipients will be eligible

Transplant Type Random selection of all transplants Allogeneic, related Allogeneic, unrelated Autologous

3-4 day audit Audit Visit 1-2 auditors Place to work All records in one location

What happens during the audit?

Audit Process Auditors compare data submitted to CIBMTR with source documentation in recipient s medical record and research chart E f d d i th dit Errors found during the audit are reviewed with center staff

What we need from you Complete and return all requested information pre-audit Have all charts for each recipient available If electronic record keeping is used: 1 computer per auditor Individual access A space to work Schedule flexibility

Error Types No Source Documentation: No supporting documentation to verify data submitted on data collection form Discrepancy: Data found on source documents that differ from data reported on data collection form Omission: Data found on source documents but not reported on data collection form

What is considered source documentation? ti

Source Document Document in which data are first recorded Permanent record kept by physicians or institutions Used to complete report forms

Source Document Examples Progress Notes & Consultations Face Sheet Referring Physician Correspondence Laboratory Reports Medication Administration Records Pathology & Radiology Reports

What type of data are audited?

Audited Data Forms included but not limited to: Pre-TED and Post-TED Comprehensive Report Forms Disease-specific Forms Infusion Form Death Data Research Database consent form Research Repository consent form

Audited Fields Critical Fields Random Fields

Critical Fields Audited for each recipient Determined to be most important t for accurate completion of outcome analyses Examples: Karnofsky/Lansky scores Date of diagnosis ANC engraftment data CMV status (recipient)

Random Fields Increases audit validity and reliability Questions may vary for each audited d recipient Examples: GVHD prophylaxis drugs Pre-transplant conditioning drug doses Pulmonary toxicities Pre-transplant laboratory results

What happens after the audit?

Database Changes Auditor makes database changes Auditors provide data manager with list of database changes (ECFs) for all discrepancy and omission errors

Audit Report Transplant Centers receive audit report approximately 8-12 weeks after the audit. General observations Discussion Comparison of previous CIBMTR audit results (if applicable) Required Corrective Action Conclusion

Current Audit Team Contact Information Deb Christianson Senior Manager, Auditing and Monitoring 612-362-3426, dchristi@nmdp.org Amy Hays Senior Clinical Research Associate 612-884-8559, ahays@nmdp.org Krista Sullivan Senior Clinical Research Associate 612-884-8514, ksulliva@nmdp.org Jody Avery Clinical Research Associate 612-617-8322, 617 javery@nmdp.org Kristin Lawman Clinical Research Associate 612-617-8329, klawman@nmdp.org Lauren Wendland d Clinical Research Associate 612-884-8616, lwendlan@nmdp.org

Questions?